select trial semaglutide nejm New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj Oral and Cardiovascular Outcomes (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis select trial semaglutide cardiovascular outcomes
Description
A 2023 analysis comparing GLP-1 drugs found that triple-receptor agonists like retatrutide produced greater reductions in caloric intake in the first two weeks compared to single or dual receptor drugs
The association among autonomic nervous system function, incident diabetes, and intervention arm in the diabetes prevention program
Metab Brain Dis 30(2):519527
To maintain the integrity of the compound, it must be stored in a cool, dark environment
References 1.Medications containing semaglutide marketed for type 2 diabetes or weight loss
